Hepatology:一项20年的社区研究:NAFLD发病率趋势及对代谢并发症、死亡率的影响

2017-09-28 MedSci MedSci原创

NAFLD发病率增加了5倍,尤其是在成年青少年患者中。NAFLD是疾病的结果,也是代谢并发症的先驱因素。代谢并发症削弱了NAFLD对死亡率的影响,免除了对心血管事件的影响。

近年来,缺乏非酒精性脂肪性肝病(NAFLD)流行病学资料,特别是NAFLD发病率资料。该研究旨在分析美国社区NAFLD发病率趋势,以及对代谢并发症(MC)、心血管(CV)、死亡率的影响。

研究者使用罗切斯特流行病学项目为研究选定对象。研究对象是在1997-2004年间被诊断为NAFLD的成人患者,这些患者来自于奥姆斯特德的一个社区。计算年发病率。采用多态模型研究分析NAFLD对MC、CV和死亡率的影响,并以4:1的年龄和性别匹配的一般人群作为参考。

研究共纳入3869例NAFLD患者(平均年龄:53岁;52%的患者为女性),15209例对照。中位随访时间是7(1-20)年。NAFLD发病率增加了5倍,从62/100,000到329/100,000人年。增加比率最高的是18-39岁的青少年人群,NAFLD发病率增加了7倍。NAFLD患者(10.2%)的10年死亡率显著高于对照(7.6%),p<0.0001。NAFLD是MC和死亡率的独立危险因素。当存在0、1、2、3件MC事件时,随着MC事件的增加,死亡风险降低,RR分别是2.16 (95% CI 1.41-3.31),1.99 (95% CI 1.48-2.66),1.75 (95% CI 1.42-2.14)和1.08 (95% CI 0.89-1.30)。仅仅当患者不存在代谢并发症时,NAFLD显著影响心血管(RR=1.96, 95% CI=1.35-2.86)。NAFLD将预期寿命缩短了4年,患者更多时间存在高代谢负荷。

NAFLD发病率增加了5倍,尤其是在成年青少年患者中。NAFLD是疾病的结果,也是代谢并发症的先驱因素。代谢并发症削弱了NAFLD对死亡率的影响,免除了对心血管事件的影响。

原始出处:

Allen AM, Terry TM, Larson JJ, et al. Nonalcoholic Fatty Liver Disease Incidence and Impact on Metabolic Burden and Death: a 20 Year-Community Study. Hepatology, 2017, Sep 23. doi: 10.1002/hep.29546.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2083904, encodeId=04502083904f8, content=<a href='/topic/show?id=d3b820e32c' target=_blank style='color:#2F92EE;'>#AFLD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2073, encryptionId=d3b820e32c, topicName=AFLD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sun May 06 14:35:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823379, encodeId=78e318233e921, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun May 13 21:35:00 CST 2018, time=2018-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757858, encodeId=1e941e57858e2, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Wed Nov 15 11:35:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395710, encodeId=b1251395e10b3, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Sep 29 15:35:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426851, encodeId=b83614268518c, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Sep 29 15:35:00 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2018-05-06 lvygwyt2781
  2. [GetPortalCommentsPageByObjectIdResponse(id=2083904, encodeId=04502083904f8, content=<a href='/topic/show?id=d3b820e32c' target=_blank style='color:#2F92EE;'>#AFLD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2073, encryptionId=d3b820e32c, topicName=AFLD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sun May 06 14:35:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823379, encodeId=78e318233e921, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun May 13 21:35:00 CST 2018, time=2018-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757858, encodeId=1e941e57858e2, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Wed Nov 15 11:35:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395710, encodeId=b1251395e10b3, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Sep 29 15:35:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426851, encodeId=b83614268518c, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Sep 29 15:35:00 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2083904, encodeId=04502083904f8, content=<a href='/topic/show?id=d3b820e32c' target=_blank style='color:#2F92EE;'>#AFLD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2073, encryptionId=d3b820e32c, topicName=AFLD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sun May 06 14:35:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823379, encodeId=78e318233e921, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun May 13 21:35:00 CST 2018, time=2018-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757858, encodeId=1e941e57858e2, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Wed Nov 15 11:35:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395710, encodeId=b1251395e10b3, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Sep 29 15:35:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426851, encodeId=b83614268518c, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Sep 29 15:35:00 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2017-11-15 丁鹏鹏
  4. [GetPortalCommentsPageByObjectIdResponse(id=2083904, encodeId=04502083904f8, content=<a href='/topic/show?id=d3b820e32c' target=_blank style='color:#2F92EE;'>#AFLD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2073, encryptionId=d3b820e32c, topicName=AFLD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sun May 06 14:35:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823379, encodeId=78e318233e921, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun May 13 21:35:00 CST 2018, time=2018-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757858, encodeId=1e941e57858e2, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Wed Nov 15 11:35:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395710, encodeId=b1251395e10b3, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Sep 29 15:35:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426851, encodeId=b83614268518c, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Sep 29 15:35:00 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2083904, encodeId=04502083904f8, content=<a href='/topic/show?id=d3b820e32c' target=_blank style='color:#2F92EE;'>#AFLD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2073, encryptionId=d3b820e32c, topicName=AFLD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sun May 06 14:35:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823379, encodeId=78e318233e921, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun May 13 21:35:00 CST 2018, time=2018-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757858, encodeId=1e941e57858e2, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Wed Nov 15 11:35:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395710, encodeId=b1251395e10b3, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Sep 29 15:35:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426851, encodeId=b83614268518c, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Sep 29 15:35:00 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2017-09-29 gwc384

相关资讯

J Hepatol:非酒精性脂肪性肝病患者发生慢性肾脏疾病风险

总之,研究结果表明,在一项包含有成年男性、女性的大型研究队列中,NAFLD与CKD进展风险相关。NAFLD可能严重影响肾脏功能,需要密切关注CKD风险。脂肪肝的存在与肾脏功能的衰退有关。因此,需要定期监测脂肪肝患者的肾脏功能。

Liver Int:生长分化因子15预测NAFLD患者进展期肝纤维化

总之,研究表明,GDF15可以作为进展期肝纤维化的一种新的生物标志物。

J Viral Hepat:肝脂肪变性和慢性乙型肝炎相关关系

慢性乙型肝炎患者,严重肝脂肪变性与肝纤维化分期增加相关。肝脂肪变性严重程度的增加与较低水平的HBV DNA水平独立相关。

Liver Int:脂肪变性影响非酒精性脂肪性肝病非侵袭性纤维化诊断结果

脂肪变性程度可能影响NAFLD患者非侵入性肝纤维化检测的诊断性能。为了优化非侵袭性纤维化评估性能,应为不同的NAFLD亚组患者定制不同的个性化应用。

Hepatology:肝纤维化分期而非非酒精性脂肪性肝炎可预测患者死亡率和发展为严重肝病的时间

在平均20年的随访中(范围:0-40),相当于13163人年,12%的NAFLD患者和2.2%的正常对照发展为严重肝病(p<0.001)。相比正常对照,严重肝病的风险随着肝纤维化分期的增加而增高。

SCI REP:非酒精性脂肪肝与冠状动脉钙化有何关系?

由此可见,该研究的发现进一步证实了NAFLD与CAC之间存在的关联,特别是在亚洲人群中。